STRATEGIC-1: Multi-line therapy trial in unresectable wild-type KRAS/NRAS/BRAF metastatic colorectal cancer—A GERCOR-PRODIGE randomized open-label phase III study.

Author:

Chibaudel Benoist1,Dourthe Louis-Marie2,Andre Thierry3,Henriques Julie4,Bourgeois Vincent5,Etienne Pierre-Luc6,Desrame Jérôme7,Carola Elisabeth8,Dupuis Olivier9,Baba-Hamed Nabil10,Auby Dominique11,Louvet Christophe12,Maillard Emmanuel13,Romano Olivier14,Tournigand Christophe15,Garcia-Larnicol Marie-Line16,Shmueli Einat Shacham17,Healey Bird Brian18,Ghiringhelli François19,De Gramont Aimery1

Affiliation:

1. Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France;

2. Clinique Sainte-Anne, Strasbourg, France;

3. Department of Medical Oncology, Hopital Saint-Antoine, APHP, Paris, France;

4. Methodology and Quality of Life Unit in Oncology (INSERM UMR 1098), University Hospital of Besançon, Besançon, France;

5. Digestive Oncology, Hopital Duchenne, Boulogne-Sur-Mer, France;

6. Medical Oncology Department, Hôpital Privé des Côtes d'Armor, Plerin, France;

7. Cancerology Institute, Hôpital Privé Jean Mermoz, Lyon, France;

8. Pôle d'Oncologie Médicale, Groupe Hospitalier Public du Sud de l'Oise, Creil, France;

9. Clinique Victor Hugo, Le Mans, France;

10. Medical Oncology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France;

11. Department of Medical Oncology, CH de Mont-de-Marsan, Hospital Layné, Mont-De-Marsan, France;

12. Medical Oncology Department, Institut Mutualiste Montsouris, Paris, France;

13. CH Annecy-Genevois, Annecy, France;

14. Medical Oncology Department, Lille Metropole Cancer Institute, Villeneuve D'ascq, France;

15. Medical Oncology Department Head, Henri Mondor University Hospital, Créteil, France;

16. Multidisciplinary Group in Oncology (GERCOR), Paris, France;

17. Cancer center, The Chaim Sheba Medical Center, Ramat Gan, Affiliated with the Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel;

18. Bon Secours Hospital Cork, Cancer Trials Ireland, and University College Cork, Cork, Ireland;

19. Medical Oncology Department, Centre Georges-François Leclerc, University of Bourgogne Franche-Comté, Dijon, France;

Abstract

3504 Background: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), anti-angiogenic and anti-epidermal growth factor receptor (EGFR) agents have become available. Ultimately, strategy trials are needed to define the optimal use and the best sequencing of these agents. Methods: Patients with previously untreated RAS/BRAF wild-type unresectable mCRC were randomly assigned (1:1 ratio) to receive either FOLFIRI-cetuximab followed by mFOLFOX6-bevacizumab (arm A) or OPTIMOX-bevacizumab followed by FOLFIRI-bevacizumab followed by EGFR mab +/- irinotecan (arm B). This trial was designed as a superiority study (hypothesis arm B > arm A) with Duration of Disease Control (DDC) as primary endpoint, defined as the sum of PFS of each active sequence of treatment (Chibaudel B, J Clin Oncol, 2011). Secondary endpoints were overall survival (OS), Time to Failure of Strategy (TFS), Progression-free survival (PFS) and response rate (RECIST version 1.1) per sequence, salvage surgery rate, safety, and Quality of life (QoL). Results: Between October 2013 and May 2019, 263 eligible patients were randomized (arm A, n = 131; arm B, N = 132). After a median follow-up of 51.2 months (95% CI 43.3-57.4), 188 events for DDC were observed. Efficacy outcomes are presented in table. Median DDC was similar in both arms (HR 0.97, 95% CI 0.72-1.29; P = 0.805). Salvage surgery for metastasis (+/- radiofrequency ablation) was done in 36 (27.5%) patients in arm A and 28 (21.2%) in arm B. Median time until definitive deterioration of QoL (global health status) were 18.3 and 18.0 months (P = 0.628). The safety profiles were consistent with the established safety profiles of each treatment regimen. Conclusions: STRATEGIC-1 is the first randomized phase III study comparing multi-line standard treatment strategies in patients with KRAS/NRAS/BRAF wild-type mCRC. This study did not meet its primary endpoint of DDC. The treatment strategy starting with FOLFIRI-cetuximab followed by mFOLFOX6-bevacizumab led to higher response rates and to a trend for better median OS exceeding 3 years. These findings may add to our understanding of treatment sequencing in mCRC. Clinical trial information: NCT01910610. [Table: see text]

Funder

ROCHE

GERCOR.

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3